Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells
| Autor: | Rafael Ríos Tamayo, Esmeralda Ríos Sánchez, Antonio Matas Hoces, Leticia García Mochón, Vicente Gimeno-Ballester, Antonio Olry de Labry Lima, Emilio Jesús Alegre-Del Rey, David Epstein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Male medicine.medical_specialty Cost effectiveness medicine.medical_treatment Cost-Benefit Analysis Hematopoietic stem cell transplantation Maintenance Chemotherapy Internal medicine medicine Humans In patient Autologous transplant Autografts Lenalidomide Multiple myeloma Aged Transplantation Cost–benefit analysis business.industry Age Factors Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Clinical trial Spain Female business Multiple Myeloma medicine.drug |
| Popis: | The objective of this article is to analyze the ratio of cost-effectiveness and budgetary impact of lenalidomide treatment in patients with multiple myeloma who have undergone autologous transplant in Spain. The analyses were based on clinical trials CALGB 100104 and IFM 2005-02, from the perspective of the National Health System. The alternatives compared were the treatment with lenalidomide against maintenance without treatment (MwT). Efficiency measures used were years of life gained (YGs) and quality-adjusted life years (QALYs). According to the CALGB 100104 trial data, the average health costs of patients who were treated with lenalidomide for 120 months was €836,534.31 and without treatment was €528,963.63. The effectiveness of the lenalidomide group was 7.59YGs (5.72 QALY) against 6.58 of MwT (4.61 QALY). The incremental cost-utility ratio (ICUR) was €277,456.72/QALY and the incremental cost-effectiveness ratio was €303,191.05/YGs. From the analysis, the IFM2005-02 trial obtained 5.13 QALY in the lenalidomide group against the 4.98 QALY in the MwT group, with an ICUR of €1,502,780.55/QALY. In terms of budgetary impact, a range between 799 and 1452 patients susceptible to receive treatment with lenalidomide was assumed in Spain. In conclusion, the results show a high ICUR and budgetary impact, which adds uncertainty about the maximum prudent duration of the treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|